ABOUT US 2017-06-14T13:11:35+00:00

ABOUT US

Management & Directors
Scientific Advisors
Business Advisors

Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug development company headquartered in Utah focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. The company was founded in 2002 with the mission to bring its new class of opioid pain therapies and addiction treatment alternatives to the healthcare community.

We believe strongly in the value to humanity of a class of potent analgesics with the potential to relieve pain and suffering without the problems of abuse and addiction, serious side effects and death from overdose. The Company believes that superior investor returns can be accomplished while delivering relief to millions of pain sufferers and opioid addicts.

Phoenix PharmaLabs welcomes your support and assistance in pursuing the goal of solving one of the world’s most vexing and pervasive problems.  Please contact us for additional information.

Management & Directors

JOHN A. LAWSON PH.D.

Founder, Chairman & Chief Scientific Officer

Dr. Lawson is responsible for the planning of R & D and the supervision and execution of all chemistry activities related to drug discovery and development.

John Lawson is an expert in medicinal and synthetic organic chemistry. As a senior Medicinal Chemist and Project Manager at Stanford Research Institute (SRI International) for 20 years, he headed the Neurochemistry R & D Group with responsibilities for the discovery and development of new compounds in neuroscience area including analgesics, anti-convulsants, anxiolytics, and stroke. While at SRI, Lawson collaborated for ten years with Dr. Toll, Chief Neuropharmacologist and Board Member of Phoenix PharmaLabs (see below), on analgesic drugs under NIH grant funding. During this period, Dr. Lawson discovered the initial class of opioids capable of relieving pain without the typical side-effect problems of morphine-like opioids. After leaving SRI, Lawson assisted in the opening of a synthetic laboratory at SynVax, Inc., in northern Utah, for the purpose of developing and patenting new drugs related to Nociceptin — a recently discovered brain chemical that modulates pain responses. Two years later, he left SynVax and founded Phoenix PharmaLabs, Inc. (PPL), for the purpose of renewing the development of non-addicting opioid compounds. John holds a BS degree with Phi Kappa Phi honors from Iowa State University and a Ph.D. from the University of Oregon. He was also a Postdoc. fellow at Syntex Corp.

WILLIAM CROSSMAN

President, CEO & Board Member

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.

Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 100 level companies. He has a proven track record of successfully commercializing emerging technologies. Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. These companies include Embedded Nanomagnetics, Inc. and Inframat Corp. (nanotechnology and life sciences), Intelepresence, Inc. (defense systems), Ensolve, Inc. (marine bioremediation products), Quantum Dynamics, Inc. (clean energy technology) and Frozen Process Technologies, Inc. (specialized manufacturing systems). As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth. The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.

TIMMY CHOU

Vice President, CFO and Board Member

Mr. Chou is responsible for the management of Company finances, corporate governance and treasury matters, including accounting and disbursements as well as the planning and execution of corporate development activities, including capital generation.

Timmy Chou’s corporate experience includes serving as a Chief Financial Officer, Controller, and CEO, as well as a management consultant for numerous companies. He is a founding partner of Spectra Consulting Group, where for more than 20 years he has performed consulting on growth issues in emerging businesses, including specialized consulting in strategic planning, cash management, capital structures, dispute mediation, and organizational re-engineering and process development. He is a serial entrepreneur and currently serves as an officer of several operating public and private companies and sits on various Boards as a director. He has participated in architecting numerous capital structures and has developed strategies for development-stage enterprises that have produced significant debt and/or equity investment. Mr. Chou is listed as an affiliate of the Wasatch Venture Network and is a member of the Association for Conflict Resolution and Utah Dispute Resolution. Timmy holds a bachelor’s degree from Brigham Young University and has pursued graduate work at the University of Utah. He also has completed training as a Microsoft Certified Systems Engineer, and completed graduate studies in mediation.

LAWRENCE TOLL PH.D.

Founder, Chief Neuropharmacologist and Board Member

Dr. Toll is responsible for the planning of R & D strategies and the supervision and/or execution of discovery pharmacology activities related to the Company’s drug development programs.

 Dr. Toll is currently Director of Neuropharmacology, Torrey Pines Institute for Molecular Studies. Prior to that he was Director of the Neuropharmacology Department at SRI International, where he conducted basic and translational research in the fields of pain and addiction and also managed contract drug screening and other R & D services performed by teams of cellular, molecular, animal, and behavioral biologists. An author of more than 100 peer-reviewed scientific papers, he is a recognized expert and leading researcher in the field of neuroscience, particularly in relation to addiction neurobiology and the pharmacology of drugs with potential addiction liability, such as opiates. Dr. Toll is a co-discoverer of the “nociceptin” opioid peptide and was part of the Opiate Research team at SRI that first researched potential non-addicting opioids in the late 1980s. Dr. Toll has performed numerous selected assessments of neurochemical drugs for the National Institute on Drug Abuse (NIDA). As part of NIDA’s Opiate and Cocaine Treatment Discovery Programs, he tested a very large number of compounds for affinities and activities at the three opioid receptors, 5 dopamine receptors, several 5-HT receptors, PCP receptors and sigma receptors. In conjunction with this project and CPDD, Dr. Toll and his team published the definitive in vitro profile of opioid- and cocaine-related ligands. In addition to standard and unknown opiate-related compounds his lab has collaborated with many medicinal chemists to characterize the activity of a large number of compounds, including PPL’s compounds. Larry holds a BA degree in chemistry from the University of California, San Diego and a Ph.D. in biological chemistry from the University of California, Los Angeles as well as a Postdoc. in biological chemistry at the University of California, Los Angeles and a Postdoc. in pharmacology at Johns Hopkins University.

CHRIS TEW

Vice President and Board Member

Mr. Tew is responsible for participating in the planning and execution of business development strategies and the active management of promotional and public relations activities and relationships as well as capital generation.

Chris Tew brings over 25 years of professional bioscience sales, marketing and business development leadership experience to the company as a sales, marketing and development executive with American Hospital Supply, CooperVision, and Alcon. Later, Mr. Tew joined Protocol Systems as Director of U.S. Sales during the company’s start-up phase soon becoming VP of Worldwide Sales. Mr. Tew played a pivotal role in driving global sales growth from $1.5 million to over $65 million when the company was sold. Mr. Tew participated in the process of taking the company public and later in completing the successful sale of the company for $145 million to Welch Allyn, Inc. Mr. Tew has been responsible throughout his career for championing many successful sales and product initiatives both inside and outside of these companies. In addition, Mr. Tew co-founded HealthWare Management Company, a healthcare software company, which was sold at a profit to Global Software. He continues to serve as a board member and in an advisory role to a variety of other companies. Chris holds a BA degree in mass communications from Brigham Young University, and completed an executive training program at Stanford University.

THEODORE H. STANLEY M.D.

Consultant and Board Member

Dr. Stanley is responsible for advising the Company with respect to its business development, capital generation, and drug development strategies.

Dr. Stanley is a Professor of Anesthesiology at the University of Utah, where he has been employed for the past 30 years, and was the Chairman and Founder or ZARS Pharma, a Salt Lake City based pharmaceutical company focusing on opioid research and creative delivery methodology. Dr. Stanley was director of research at the University of Utah for over 20 years and is internationally known for his developmental work on opioids, other intravenous anesthetics and novel drug delivery techniques. In 1985, he co-founded Anesta, a drug delivery company with two FDA-approved products: fentanyl Oralet and Actiq. Dr. Stanley is an often invited speaker on Anesthesiology and the future of drug delivery topics throughout the world. Dr. Stanley was selected as the Utah Entrepreneur of the Year by the Wasatch Venture Group in 2006. Ted graduated from Columbia College and then Columbia University Medical School before completing a residency in anesthesiology at the Columbia-Presbyterian Medical Center.

Scientific Advisors

Mary Jeanne Kreek, M.D.

Consultant, Addictive Diseases and Therapy

Dr. Kreek is Senior Attending Physician and Patrick E. and Beatrice M. Haggerty Professor, Head of Laboratory of Biology of Addictive Diseases, The Rockefeller University. She is the recipient of numerous professional awards including:  Betty Ford Award, Association for Medical Education and Research in Substance Abuse, 1996; Specific Recognition Award, Research in Science of Addiction, Executive Office of the President – Office of National Drug Control Policy 1998; R. Brinkley Smithers Distinguished Scientist Award, American Society of Addiction Medicine, 1999; Nathan B. Eddy Memorial Award for Life-time Excellence in Drug Abuse Research, College on Problems of Drug Dependence, 1999; Fellow, New York Academy of Sciences, 2000; Columbia University College of Physicians and Surgeons Alumni Association – Gold Medal for Distinguished Achievements in Academic Medicine, 2004; Marian W. Fischman Memorial Lectureship Award, College on Problems of Drug Dependence, 2005; President, International Narcotics Research Conference 2002-2006. Dr Kreek holds a BA in Chemistry from Wellesley College and an MD from Columbia College of Physicians and Surgeons, Sigma Xi, Phi Beta Kappa: Durant Scholar.

Gary Robinson, Ph.D.

Consultant, Preclinical and Clinical Trials and Regulatory Affairs

Dr. Robinson is the principal of PhaseDesign Research with deep experience in primary pharmacology, IND-enabling preclinical studies, Phase I, II and III clinical trials, regulatory affairs and drug product manufacture. Principal project work includes: IND submissions & maintenance (~55 FDA submissions + 3 TPD & 1 EMEA submission), project planning & execution of IND enabling studies (>25 preclinical studies from set-up to final report), clinical study set-up/oversight/report completion (6 NCE first-in-man Phase 1 studies), CMC work (includes API & product manufacture and bioanalytical support work). Dr. Robinson is a Charter Member of an NIH NINDS Translational Special Review Group grant review panel member as well as an invited NSF SBIR grants review panel member for drug delivery, biomedical engineering, and biomedical imaging projects. Dr. Robinson holds a BS degree in Biochemistry from Queen Elizabeth College, University of London, UK and a Ph.D. from King’s College, University of London, UK.

Shayne Gad, Ph.D.

Consultant, Toxicology and Regulatory Affairs

Dr. Gad is Principal, Gad Consulting Services, a twenty year old consulting firm with over 300 pharmaceutical companies as clients. He has more than 35 years of broad-based experience in toxicology, drug development, statistics and risk assessment and has authored or edited 44 published books in these fields. He is the recipient of the American College of Toxicology Lifetime Contribution Award. He has direct involvement in the preparation of INDs (96 successful to date), NDA, PLA, ANDA, 510(k), IDE, CTD, clinical data bases for Phase I and II studies, and PMAs. He has consulted for FDA, EPA AND NIH, and has trained reviewers and been an expert witness for the FDA. Shayne holds two BS degrees from Whittier College in Chemistry and Biology, and a Ph.D. in Pharmacology / Toxicology from the University of Texas DABT, ATS.

John Mendelson, M.D.

Consultant, Clinical Trial Design

Dr. Mendelson is Senior Scientist, Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute and is also Clinical Professor of Medicine at the University of California, San Francisco. He is also a member of the FDA Analgesic Drugs Advisory Committee. He is the former Chair of the California Pacific Medical Center Institutional Review Board. He is Selected, Best Doctors USA and has frequently served as Section Chair of the American Society of Clinical Pharmacology and Therapeutics. He has specific expertise in the design and supervision of human clinical trials of controlled substances. John holds a BA in Biology from Antioch College and an MD from the University of California, San Francisco.

Mei-Chuan (Holden) Ko, Ph.D.

Consultant, NHP Studies

Dr. Ko is Professor, Department of Physiology & Pharmacology, Wake Forest University School of Medicine

Business Advisors

David Batista

Consultant, Investment Banking

Mr. Batista is the Senior Managing Director of Viriathus Holdings and Viriathus Capital. He has over 20 years of diversified Wall Street experience as a trader and investment banker. From December 2004 to August 2008, he was a Managing Director at HPC Capital Management and was responsible for their New York Private Capital Markets activities. He was also a Vice President of NASDAQ trading at SoundView Technology Group, a technology-focused research and trading boutique. While at SoundView, he was responsible for making markets in various technology based sectors. Prior to joining SoundView, he was a senior NASDAQ trader at JW Charles Securities and its successor JW Genesis Securities. While at JW, he was largely responsible for the firm’s entry into the institutional equities trading arena by leveraging their substantial retail equities order flow. He began his professional career with Lehman Brothers as an investment banking analyst where he worked on numerous mergers & acquisitions and corporate financing activities. He subsequently began his trading career on Lehman’s NASDAQ desk in February 1996. He received a Bachelor of Science Degree in Business Administration with a dual concentration in Finance and International Marketing from C.W. Post College.

David Battleman, MD.

Consultant, Investment Banking

Dr. Battleman is Principal and Founder of TrueNorth Lifesciences and is also Managing Director of Viriathus Capital. He is a seasoned healthcare executive with over 15 years of experience, spanning academia, industry and management consulting.  He provides consulting and financial advisory services to highly innovative early stage lifescience companies to accelerate and optimize drug and / or device commercialization. Earlier in his career, Dr. Battleman served as a senior principal in both the Health Economics and Global Pricing & Market Access (P&MA) practices within IMS Health, a Fortune 500 company providing life science data and consulting services to the pharmaceutical industry. And prior to joining IMS, Dr. Battleman was a management consultant in the life science practice of Bain & Company, a leading strategy and management consulting firm. Within industry, Dr. Battleman served for several years as senior director / executive director for Pfizer Pharmaceuticals where he was responsible for developing commercial strategies across Pfizer’s cardiovascular portfolio, ranging from early-stage to marketed products. And within academia, he was an assistant professor of public health and internal medicine at Cornell University’s Weill Cornell Medical College. Dr. Battleman holds an M.D. from Weill Cornell Medical College, an M.B.A. from the University of Pennsylvania’s Wharton School of Business, a M.Sc. in epidemiology from the Harvard School of Public Health, and a B.A. in natural sciences from The Johns Hopkins University.

Anne Maxwell, J.D. Ph.D.

Patent Attorney

Dr. Maxwell is a partner at Cantor Colburn LLP where she has been practicing with since 2003, specializing in the preparation and prosecution of patent applications for small molecule drugs, assays, and pharmaceutical formulations. Dr. Maxwell also is an expert manager of foreign prosecution, with extensive experience in coordinating worldwide prosecution for pharmaceutical patent applications. Cantor Colburn is the sixth largest and fastest growing patent law firm in the US and has been recognized in “Best Law Firms” by U.S. News. Dr. Maxwell was previously a Patent Agent and Post-Doctoral Fellow at Neurogen Corporation. She is admitted to practice in Connecticut and New York, and is registered to practice before the United States Patent and Trademark Office. She received her B.A and B.Sc. from the University of Illinois in 1988, received her Ph.D. in biophysical chemistry from Yale University in1995, and obtained a J.D. from the University of Connecticut School of Law in 2005.